Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12
| Författare |
Sara Rhost Sai Kiran Sedimbi N. Kadri Susanna Cardell |
|---|---|
| Publicerad i | Scandinavian Journal of Immunology |
| Volym | 76 |
| Nummer/häfte | 3 |
| Sidor | 246-255 |
| ISSN | 0300-9475 |
| Publiceringsår | 2012 |
| Publicerad vid |
Institutionen för biomedicin, avdelningen för mikrobiologi och immunologi |
| Sidor | 246-255 |
| Språk | en |
| Länkar |
dx.doi.org/10.1111/j.1365-3083.2012... |
| Ämnesord | invariant nkt cells, immune-response, tumor-immunity, ulcerative-colitis, antitumor-activity, self glycolipids, cross-regulation, virus-infection, cutting edge, recognition, rcelli s, 1993, journal of experimental medicine, v178, p1, llabona p, 1994, journal of experimental medicine, v180, p1171 |
| Ämneskategorier | Immunologi inom det medicinska området |
Natural killer T (NKT) lymphocytes are a beta T cells activated by lipid-based ligands presented on the non-polymorphic CD1d-molecule. Type I NKT cells that carry an invariant Va14 (in the mouse) or Va24 (in humans) T cell receptor a-chain rearrangement have received significant attention for their involvement in a diversity of immune reactions. Their sister population, CD1d-restricted type II NKT cells, has been more difficult to study because of the lack of molecular markers that specify these cells. In the last few years, however, significant progress has been made, demonstrating that type II NKT cells have unique functions in immune responses to tumours and infections, in autoimmunity, obesity and graft-versus-host disease. Type II NKT cells appear more frequent than type I NKT cells in humans and accumulate in certain diseases such as ulcerative colitis, hepatitis and multiple myeloma. Recently, novel type II NKT cell ligands have been identified, and it is becoming clear that the type II NKT cell population may be oligoclonal. Here, we review the recent progress in the study of type II NKT cells, supporting the view that type II NKT cells may be attractive targets for immunotherapy.
GÖTEBORGS UNIVERSITET • Box 100 • 405 30 Göteborg • Telefon: 031 786 0000
Kontakt • Organisationsnummer: 202100-3153 • Om webbplatsen
Facebook
Twitter
Instagram
Youtube